Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) rose 4.2% on Friday following a disclosed insider purchase by a company director.
According to a Form 4 filed with the Securities and Exchange Commission, director G. Leonard Baker Jr. acquired a total of 100,000 shares of Corcept common stock on March 17. The filing breaks the purchase down into two weighted-average tranches: 75,782 shares at a weighted average price of $33.0022 and 24,218 shares at a weighted average price of $33.5633.
Those transactions increased Baker's direct stake to 1,146,631 shares. The Form 4 also lists Baker's indirect holdings: 3,308,303 shares are held indirectly through a limited partnership, and 1,095,262 shares are held indirectly through a trust. In his capacities, Baker serves as a trustee of the trust that is the general partner of the limited partnership, and he is also a trustee of the trust that holds the indirect shares.
The filing notes the purchases were executed in multiple transactions at prices spanning $32.43 to $33.68 per share. The disclosure of insider purchases is a routine regulatory requirement; while such activity can be interpreted by market participants as a sign of confidence from company insiders, it does not constitute a guarantee of future performance.
Details of the purchase
- Transaction date: March 17.
- Total shares purchased by Baker: 100,000.
- Weighted-average prices reported: $33.0022 for 75,782 shares and $33.5633 for 24,218 shares.
- Price range across transactions: $32.43 to $33.68 per share.
Holdings after the transactions
- Direct holdings held by Baker: 1,146,631 shares.
- Indirect holdings through a limited partnership: 3,308,303 shares.
- Indirect holdings through a trust: 1,095,262 shares.
- Roles noted: Baker is trustee of the trust that serves as general partner of the limited partnership and trustee of the trust that holds the indirect shares.
Market interpretation
Market observers commonly watch Form 4 filings for signals about insider sentiment. The filing in this case documents the purchase details and the director's broader ownership structure, but the regulatory disclosure itself does not provide guidance on future company performance.